Battling the pandemic by commercializing COVID-19-fighting technology
Share this story

Adapting a detection method called Enzyme Linked Mass Spectrometric Assay (ELiMSATM) to accurately diagnose and assess present and past COVID-19 infections is raising hopes during a challenging time.

Ryerson University’s Analytical Biochemistry Lab is partnering with YYZ Pharmatech Inc., National Taiwan University and St. Michael’s Hospital to commercialize the ultrasensitive method, which helps prevent false negatives and positives, leading to fewer COVID-19 infections.

By adopting previous research conducted by the partnership, the technology provides patients with a highly accurate assessment of whether they have the virus or have had it in the past.

For more information, visit Ryerson University.

More Stories
Helping local companies produce COVID-19 test kits
Preparing plants for climate change
Researchers examine new method to predict premature birth